Stock Ratings / Health Care / RNXT / insiders

OSTX (42) ZYBT (40) FBIO (39) MNOV (30) ⌘ Pro Terminal →

RenovoRx Inc. (RNXT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is RNXT trading relative to its 50-day, 200-day, and 52-week technical levels?

RNXT last traded at $1.33 (-10.74% on volume of 376,402 shares), positioning the stock -14.74% below its 50-day simple moving average ($1.56) and +20.91% above its 200-day simple moving average ($1.10). Across its 52-week range of $0.70 to $2.59, RNXT sits at the 33.3% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.16 to $1.50).

Q: Are RNXT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RNXT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.33 -10.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.30

RenovoRx Inc. (RNXT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $67.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNXT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, RenovoRx Inc. (NASDAQ: RNXT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.33 (-10.74% 1D, market cap $67.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RNXT ranks #817 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNXT compare to OSTX and ZYBT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNXT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 70.9%, and ROIC of -35.0%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNXT?

▼

Per RNXT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574094), RenovoRx Inc. generated $1.1M in revenue (+2511.6% YoY), -$11.2M in net income, and -$11.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.30 (-2.12%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNXT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY RNXT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 0.40 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.28-10.9% Next Q

Q2 (-2Q)

Grade E$1.14+13.2% Next Q

Q3 (-1Q)

Grade E$1.29+3.1% Next Q

Current

Grade E$1.33-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNXT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNXT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.40) forces dealer call-delta covering toward $2.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNXT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RNXT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RNXT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RNXT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RNXT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNXT)

✓Walkthrough of RNXT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RNXT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +56.47%▲ ASCENDING TRIANGLE

2026-10-30O $1.49H $1.50L $1.30C $1.33VOL 376.4K

SUP: $1.14SMA50: $1.56SMA200: $1.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNXT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNXT Butterfly Map → + Track RNXT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNXT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNXT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RNXT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNXT)

Health Care Rank #817 of 1016 ⚔️ OSTX vs RNXT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNXT vs. OSTX, ZYBT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, RenovoRx Inc. (RNXT) ranks #817 by composite RQD confidence (31/100, grade E) and #713 by equity capitalization ($67.2M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with RNXT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RNXT ACTIVE RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	Benchmark Subject
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-rnxt →
ZYBT Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	/zybt-vs-rnxt →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-rnxt →
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-rnxt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001574094

In its most recent audited fiscal period (FY2025, filed 2025-12-31), RenovoRx Inc. (RNXT) reported GAAP revenue of $1.1M (+2511.6% vs. FY2024 revenue of $43.0K ) , GAAP net income of -$11.2M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (-20.1% YoY). On the balance sheet, RNXT closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: 0.40, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.1M	-$11.2M	-$11.0M	-$11.0M	$8.1M	—
FY2024 (FY)	2024-12-31	$43.0K	-$8.8M	-$9.1M	-$9.1M	$8.1M	—
FY2023 (FY)	2023-12-31	$0	-$10.2M	-$10.3M	-$10.3M	—	—

3. RNXT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RNXT compare to OSTX and ZYBT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RNXT?

Where is RNXT trading relative to its 50-day, 200-day, and 52-week technical levels?

RNXT last traded at $1.33 (-10.74% on volume of 376,402 shares), positioning the stock -14.74% below its 50-day simple moving average ($1.56) and +20.91% above its 200-day simple moving average ($1.10). Across its 52-week range of $0.70 to $2.59, RNXT sits at the 33.3% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.16 to $1.50).

RNXT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RNXT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RNXT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: RNXT RQD Cockpit RNXT 12M Forecast RNXT Earnings & Move RNXT Dividends & DRIP RNXT Insiders & 13F RNXT Whale Options RNXT Profit Sankey RNXT News & Why